Key result
Assessment of cardiovascular data from the APPROVe trial highlights methodological issues in time-to-event analyses, including proportional hazards assumptions and follow-up for long-term treatments.
This paper highlights important methodological issues regarding the analysis and interpretation of time-to-event safety endpoints in long-term randomized trials, using the APPROVe trial as a case study.
Answers are grounded in this paper and cite their sources.
Requires cautious interpretation of time-to-event safety data from long-term trials; leaves open optimal analytic methods.
The Adenomatous Polyp Prevention on Vioxx (APPROVe) trial1 compared rofecoxib with placebo in the prevention of recurrent colorectal polyps, but the researchers also collected data on adverse cardiovascular events, including confirmed serious thrombotic events. Assessment of the cardiovascular data raises important issues about the analysis and interpretation of a time-to-event end point in a randomized, placebo-controlled trial evaluating a long-term treatment. These issues include the appropriate period of follow-up for safety outcomes after the discontinuation of treatment; the purpose and implications of checking the assumption of proportional hazards, which underlies the commonly used log-rank test and Cox model; and what . . .
No takes yet. Share an insight, caveat, or question.
Stephen W. Lagakos (2006) conducted a review in Recurrent colorectal polyps. Rofecoxib vs. Placebo was evaluated on Adverse cardiovascular events, including confirmed serious thrombotic events. Assessment of cardiovascular data from the APPROVe trial highlights methodological issues in time-to-event analyses, including proportional hazards assumptions and follow-up for long-term treatments.
Synapse has enriched 10 related papers. Consider them for comparative context: